News for Lipocine Inc. (LPCN)

On June 10, 2025, HC Wainwright & Co. reaffirmed its optimistic outlook on Lipocine (LPCN) by reiterating a 'Buy' rating. Analyst Yi Chen maintained the price t

PR NewswireSALT LAKE CITY, June 9, 2025 New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescriptions written ann

Lipocine (LPCN) has taken a significant step forward with its licensing partner, Verity Pharma, by filing a New Drug Submission (NDS) for TLANDO in Canada. This

TLANDO, developed by Lipocine (LPCN), seeks approval in the Canadian market as the first FDA-approved oral TRT without dose titration. The Canadian TRT

Analyst Yi Chen from H.C. Wainwright has initiated coverage on Lipocine (LPCN), giving it a Buy rating and setting a target price of $8. Lipocine's initial comm

PR NewswireSALT LAKE CITY, May 22, 2025 SALT LAKE CITY, May 22, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging i

FDA grants fast track designation to Lipocine's LPCN 1148 for treating sarcopenia in patients with decompensated cirrhosis. LPCN 1148 featured as a 'Fir

PR NewswireSALT LAKE CITY, May 14, 2025 SALT LAKE CITY, May 14, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging i

Lipocine Inc. (LPCN) will present at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025, at 4:00 pm ET. The virtual presentation will be access

PR NewswireSALT LAKE CITY, May 6, 2025 SALT LAKE CITY, May 6, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its

Lipocine (LPCN) has finalized a license and supply agreement with Ache Laboratorios Farmaceuitcos, granting them exclusive rights to market TLANDO in Brazil. Th

Lipocine Inc. (LPCN) secures agreement with Aché Laboratórios for exclusive marketing of TLANDO® in Brazil. The Brazilian prescription testosterone m

PR NewswireSALT LAKE CITY, March 13, 2025 SALT LAKE CITY, March 13, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveragi

Lipocine reports FY revenue of $11.19M and GAAP EPS of $0.00. Discover financial highlights and insights into the company's performance.

PR NewswireSALT LAKE CITY, March 12, 2025 SALT LAKE CITY, March 12, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveragi

PR NewswireSALT LAKE CITY, Nov. 18, 2024 SALT LAKE CITY, Nov. 18, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging

Lipocine Inc. (LPCN), a biopharmaceutical company, Thursday announced positive data from the Phase 1 study of oral brexanolone, a proprietary bioidentical neuroactive steroid (NAS) being developed for the treatment of post-partum depression (PPD).

Lipocine reports promising oral brexanolone study results

The rising demand for maternal mental health services is largely due to the increasing incidence of conditions like postpartum depression, dysthymia,...